Hemoglobin-Based Artificial Oxygen Carriers

Abstract:

Hemoglobin-based oxygen carriers (HBOCs) have emerged as potential red blood cell substitutes, offering longer shelf life, blood type independence, and efficient oxygen transport. They hold promise in various medical contexts, from restoring tissue oxygen to treating septic shock and preventing organ failure.
However, HBOCs have challenges like renal toxicity and hypertension, prompting
ongoing research for refinement. They provide alternatives to traditional transfusions, catering to specific patient needs, including those with religious objections and pre-term newborns. Clinical trials with HBOCs raise ethical concerns, emphasizing transparency and community involvement. HBOCs are versatile, with applications in trauma care, organ preservation, and hypoxic conditions. Successful integration hinges on addressing safety issues, immune responses, and regulatory considerations. While HBOCs hold promise, addressing challenges like oxygen release instability and regulatory hurdles is crucial for safe and effective use. Continued research is vital for realizing their otential while upholding patient safety and ethical standards.

View PDF